Back to Search
KIERSTYN GILLOOLY, PHARM.D.
PHARM.D.
Pharmacist
NPI: 1922600162Individual
Specialties, Licenses & Credentials
PharmacistPrimary
Pharmacist
Code: 183500000X
2015026245(MO)
Research & Publications (15)
Periodic, partial inhibition of IkappaB Kinase beta-mediated signaling yields therapeutic benefit in preclinical models of rheumatoid arthritis.
PMID 19652024·J Pharmacol Exp Ther·2009
7-preclinical
Synthesis, initial SAR and biological evaluation of 1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-amine derived inhibitors of IkappaB kinase.
PMID 19376699·Bioorg Med Chem Lett·2009
7-preclinical
Synthesis and SAR of new pyrrolo[2,1-f][1,2,4]triazines as potent p38 alpha MAP kinase inhibitors.
PMID 18364256·Bioorg Med Chem Lett·2008
7-preclinical
Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
PMID 18359226·Bioorg Med Chem Lett·2008
8-other
The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)-A potent and efficacious p38alpha MAP kinase inhibitor.
PMID 18313298·Bioorg Med Chem Lett·2008
7-preclinical
Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors.
PMID 18072718·J Med Chem·2008
7-preclinical
Synthesis and structure-activity relationship of imidazo(1,2-a)thieno(3,2-e)pyrazines as IKK-beta inhibitors.
PMID 17540562·Bioorg Med Chem Lett·2007
7-preclinical
2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor.
PMID 17154512·J Med Chem·2006
7-preclinical
A selective small molecule agonist of the melanocortin-1 receptor inhibits lipopolysaccharide-induced cytokine accumulation and leukocyte infiltration in mice.
PMID 16888084·J Leukoc Biol·2006
7-preclinical
5-Cyanopyrimidine derivatives as a novel class of potent, selective, and orally active inhibitors of p38alpha MAP kinase.
PMID 16190753·J Med Chem·2005
7-preclinical
The discovery of orally active triaminotriazine aniline amides as inhibitors of p38 MAP kinase.
PMID 15566298·J Med Chem·2004
7-preclinical
A highly selective inhibitor of I kappa B kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice.
PMID 13130486·Arthritis Rheum·2003
7-preclinical
Rational design and synthesis of an orally active indolopyridone as a novel conformationally constrained cannabinoid ligand possessing antiinflammatory properties.
PMID 12747783·J Med Chem·2003
7-preclinical
C-3 Amido-indole cannabinoid receptor modulators.
PMID 12161142·Bioorg Med Chem Lett·2002
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 3721 W TRUMAN BLVD
JEFFERSON CITY, MO 65109 - Phone
- (573) 634-2628
Quick Facts
- NPI
- 1922600162
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 15
Are you this provider?
Claim Your Profile